ClinicalTrials.gg
CompletedNCT05102656Updated Nov 10, 2026

Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic

An interventional study of Best Practice and Discussion in COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2021, registered Oct 2021).
Updated Nov 10, 2026Now CompletedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in COVID-19 by M.D. Anderson Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. COVID-19 · M.D. Anderson Cancer Center.

Started
2021
with 1 other
No phase
3 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in COVID-19 by M.D. Anderson Cancer Center, this one is one of 2 that started in 2021, is one of 3 with no phase, and was the 14th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

5 of the 14 studies in COVID-19 by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in COVID-19 by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This study investigates patients' perceptions of their doctor's or nurse's empathy during an in-person interaction with the doctor or nurse wearing personal protective equipment (PPE) compared to during a video interaction with the doctor or nurse without PPE. The goal of this research study is to learn whether patients who visit the Acute Cancer Care Center at MD Anderson believe they get better (more empathetic) care from doctors who visit them in person wearing PPE or from doctors who visit them by video call and do not wear PPE.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine whether patients perceive their healthcare practitioner as more empathetic during an in-person interaction with the practitioner wearing personal protective equipment (PPE), or during a video interaction without the need for PPE.

SECONDARY OBJECTIVES:

I. To assess whether certain physicians perform better with video whereas others perform better in person.

II. To characterize generational differences in patient perception of healthcare practitioner empathy during an in person interaction with the practitioner wearing PPE, or during a video interaction without the need for PPE.

OUTLINE: After initial visit, patients are randomized to 1 of 2 groups.

GROUP A (NO PPE): Patients receive standard of care via video call with treating physician.

GROUP B (WEARING PPE): Patients receive standard of care in-person physician visits.

03

Conditions studied

  • COVID-19 Infection
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Malignant Solid Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >= 18 years old
  • Able to speak and write in English
  • Able to understand and willing to sign a written document
  • Willing and able to complete the study assessment(s)

Exclusion criteria

Exclusion Criteria:

  • Refuses to participate
  • Too ill to participate, in the estimation of the patient's physician
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Other
    Group A (video call)

    Patients receive standard of care via video call with treating physician.

    Procedure: Discussion · Other: Questionnaire Administration

  • Other
    Group B (in-person)

    Patients receive standard of care in-person physician visits.

    Other: Best Practice · Other: Questionnaire Administration

Interventions

  • OtherBest Practice

    Physician conversations occur in-person

    Also known as: standard of care, standard therapy

  • ProcedureDiscussion

    Physician conversations occur via video call

    Also known as: Discuss

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Patients' perceptions of healthcare provider empathy

    Univariate linear regression analysis will be used to determine the association between the approach (in-person interaction/with personal protective equipment \[PPE\] versus video interaction/without PPE) and the composite scores or scores for each question (for each of the two tools \[the CARE Measure and the linear empathy tool\]).

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Nov 2026, 65 months.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 65 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Feb 2027 → Nov 2026 and completion Feb 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2021
First posted
Nov 1, 2021
StartActual
Jun 2, 2021
Primary completionActual
Nov 3, 2026was Feb 2027
CompletionActual
Nov 3, 2026was Feb 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Primary completion
Feb 2, 2027→Nov 3, 2026 (actual)
Nov 10, 2026
Study completion
Feb 2, 2027→Nov 3, 2026 (actual)
Nov 10, 2026
Documents
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Documents Informed consent form ↗ posted
    Primary completion Feb 2, 2027→Nov 3, 2026 (now actual)
    Study completion Feb 2, 2027→Nov 3, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05102656
Responsible party
Sponsor
First posted
Nov 1, 2021
Start date
Jun 2, 2021
Primary completion
Nov 3, 2026
Completion
Nov 3, 2026
Last update
Nov 10, 2026

Study contacts

Kumar Alagappan
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion